Abbott Laboratories vs. ArriVent BioPharma, Inc. Common Stock
Abbott Laboratories and ArriVent BioPharma, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| ABT | AVBP | |
|---|---|---|
| Market Cap | $173.21 billion | $1.40 billion |
| Revenue (TTM) | — | — |
| Net Income (TTM) | — | $-163,735,000 |
ABT leads on 1 of 1 size & scale factors.
Valuation
| ABT | AVBP | |
|---|---|---|
| Price / Book | — | 3.83 |
ABT and AVBP split the valuation factors evenly.
Profitability
| ABT | AVBP | |
|---|---|---|
| Return on Equity | — | -44.63% |
ABT and AVBP split the profitability factors evenly.
Dividend
| ABT | AVBP | |
|---|---|---|
| Dividend Yield | 2.57% | — |
ABT and AVBP split the dividend factors evenly.
Risk & Sentiment
| ABT | AVBP | |
|---|---|---|
| Short Interest | 0.57% | 0.04% |
AVBP leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, AVBP overview, AVBP financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.